**Claims**

1. An immediate release solid oral dosage form comprising a pharmaceutically acceptable salt of AP1189 ((*E*)-*N*-[1-(2-nitrophenyl)-1-*H*-pyrrole-2-yl-allylideneamino]-guanidine) of formula I:




Formula I,

including tautomeric and stereoisomeric forms thereof,
wherein said pharmaceutically acceptable salt is selected from the group consisting of:
(*E*)-*N*-[1-(2-nitrophenyl)-1-*H*-pyrrole-2-yl-allylideneamino]-guanidinium acetate, including tautomeric and stereoisomeric forms thereof; and
(*E*)-*N*-[1-(2-nitrophenyl)-1-*H*-pyrrole-2-yl-allylideneamino]-guanidinium succinate, including tautomeric and stereoisomeric forms thereof;
and further comprising at least one pharmaceutically acceptable excipient selected from the group consisting of a binder, a disintegrant and a wetting agent.

2. The immediate release solid oral dosage form according to claim 1, wherein the pharmaceutically acceptable salt of AP1189 is (*E*)-*N*-[1-(2-nitrophenyl)-1-*H*-pyrrole-2-yl-allylideneamino]-guanidinium acetate, including tautomeric and stereoisomeric forms thereof (AP1189 acetate).

3. The immediate release solid oral dosage form according to claim 1, wherein the pharmaceutically acceptable salt of AP1189 is (*E*)-*N*-[1-(2-nitrophenyl)-1-*H*-pyrrole-2-yl-allylideneamino]-guanidinium succinate, including tautomeric and stereoisomeric forms thereof (AP1189 succinate).

4. The immediate release solid oral dosage form according to any one of claims 1-3, wherein said solid oral dosage form is an immediate release tablet.

5. The immediate release solid oral dosage form according to any one of claims 1-4, wherein not less than 80% of the pharmaceutically acceptable salt of AP1189 is dissolved into solution in 15 minutes at gastric pH in the gastric acid in the stomach.

6. The immediate release solid oral dosage form according to any one of claims 1-5, wherein not less than 80% of the salt is dissolved into aqueous solution in 15 minutes at a pH of 1 to 3, using a USP 2 paddle equipment at 37 °C at a rotation speed of 50 rpm.

7. The immediate release solid oral dosage form according to any one of claims 1-6, wherein not less than 80% of the salt is dissolved into aqueous solution in 15 minutes at a pH of 1.2, using a USP 2 paddle equipment at 37 °C at a rotation speed of 50 rpm.

8. The immediate release solid oral dosage form according to any one of claims 1-7, wherein said solid oral dosage form comprises said pharmaceutically acceptable salt of AP1189 in an amount of 25 mg to 250 mg (calculated as the free base); and wherein not less than 80% of the salt is dissolved into aqueous solution in 15 minutes at a pH of 1 to 3, using a USP 2 paddle equipment at 37 °C at a rotation speed of 50 rpm.

9. The immediate release solid oral dosage form according to any one of claims 1-8, wherein $C_{max}$ of the solid oral dosage form is not less than 180 ng/mL, such as not less than 200 ng/mL, such as not less than 225 ng/mL, such as not less than 250 ng/mL, such as not less than 275 ng/mL, such as not less than 300 ng/mL, such as not less than 350 ng/mL, such as not less than 400 ng/mL, such as not less than 450 ng/mL, such as not less than 500 ng/mL, such as not less than 600 ng/mL, such as not less than 700 ng/mL, such as not less than 800 ng/mL, such as not

less than 900 ng/mL, such as not less than 1000 ng/mL, such as not less than 1200 ng/mL, such as not less than 1400 ng/mL, such as not less than 1600 ng/mL, such as not less than 1800 ng/mL, such as not less than 2000 ng/mL, such as not less than 2200 ng/mL, such as not less than 2400 ng/mL, such as not less than 2600 ng/mL, such as not less than 2800 ng/mL, such as not less than 3000 ng/mL, such as not less than 3200 ng/mL, such as not less than 3400 ng/mL, such as not less than 3600 ng/mL after administration of a single dose of a pharmaceutically acceptable salt of AP1189.

10. The immediate release solid oral dosage form according to any one of claims 1-9, wherein the pharmaceutically acceptable salt of AP1189 is present at a dosage of about 25 mg to about 650 mg AP1189 per dosage form, such as about 25 mg, such as about 50 mg, such as about 100 mg, such as about 150 mg, such as about 200 mg, such as about 250 mg, such as about 300 mg, such as about 350 mg, such as about 400 mg, such as about 450 mg, such as about 500 mg, such as about 550 mg, such as about 600 mg, such as about 650 mg of the pharmaceutically acceptable salt of AP1189 (calculated as free base).

11. The immediate release solid oral dosage form according to any one of claims 1-10, wherein the pharmaceutically acceptable salt of AP1189 is a polymorphic form of (*E*)-*N*-[1-(2-nitrophenyl)-1-*H*-pyrrole-2-yl-allylideneamino]-guanidinium acetate, including tautomeric and stereoisomeric forms thereof (AP1189 acetate), or a polymorphic form of (*E*)-*N*-[1-(2-nitrophenyl)-1-*H*-pyrrole-2-yl-allylideneamino]-guanidinium succinate, including tautomeric and stereoisomeric forms thereof (AP1189 succinate).

12. Use of a pharmaceutically acceptable salt of AP1189 ((*E*)-*N*-[1-(2-nitrophenyl)-1-*H*-pyrrole-2-yl-allylideneamino]-guanidine), including tautomeric and stereoisomeric forms thereof, selected from the group consisting of:
(*E*)-*N*-[1-(2-nitrophenyl)-1-*H*-pyrrole-2-yl-allylideneamino]-guanidinium acetate including tautomeric and stereoisomeric forms thereof, and
(*E*)-*N*-[1-(2-nitrophenyl)-1-*H*-pyrrole-2-yl-allylideneamino]-guanidinium succinate including tautomeric and stereoisomeric forms thereof,

in the manufacture of a medicament for treatment of a disease selected from the group consisting of kidney disease, an arthritic disease such as rheumatoid arthritis, an inflammatory viral disease or disorder such as a viral respiratory disease or disorder, a cardiovascular disease, atherosclerosis, a systemic inflammatory disorder such as an autoimmune disorder,
wherein said medicament is an immediate release solid oral dosage form according to any one of the preceding claims.

13. The immediate release solid oral dosage form according to any one of claims 1-11, or the use according to claim 12, wherein said pharmaceutically acceptable salt of AP1189 is to be administered in an amount of 1 mg to 1000 mg, such as 1 to 5 mg, 5 to 10 mg, 10 to 15 mg, 15 to 20 mg, 20 to 25 mg, 25 to 50 mg, 50 to 75 mg, 75 to 100 mg, 100 to 125 mg, 125 to 150 mg, 150 to 175 mg, 175 to 200 mg, 200 to 250 mg, 250 to 300 mg, 300 to 350 mg, 350 to 400 mg, 400 to 450 mg, 450 to 500 mg, 500 to 600 mg, 600 to 700 mg, 700 to 800 mg, 800 to 900 mg, or 900 to 1000 mg of the pharmaceutically acceptable salt of AP1189, per dosage (calculated as the free base).

14. The immediate release solid oral dosage form according to any one of claims 1-11, or the use according to claims 12-13, wherein said pharmaceutically acceptable salt of AP1189 is to be administered once a day (QD), twice a day (BID) or three times a day (TID).

15. The immediate release solid oral dosage form according to any one of claims 1-11, or the use according to claims 12-14, wherein said pharmaceutically acceptable salt of AP1189 is to be administered at a once daily dosage of 1 to 1000 mg.